11 August 2026

$250,000 in Funding Received under Financing Facility

Argent BioPharma Ltd (**ASX: RGT**) (**Argent** or the **Company**) confirms that it has received A$250,000 in funding under the A$11 million convertible securities financing agreement with C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC[1], both United States-based institutional funds (**A$11m Financing Agreement**).

The Company will seek shareholder approval to issue C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC 275,000 convertible notes with a face value of A$1.00 each. Consistent with the terms of the A$11m Financing Agreement, and also subject shareholder approval at an upcoming general meeting of shareholders, Argent will also issue C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC 2,010,724 unlisted options, each exercisable at A$0.09325, expiring 36 months from the date of issue.

The A$250,000 of funds received will be used as working capital to fund RGT's ongoing operations.

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
Chairman
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its lead assets, CannEpil® and CimetrA®, are being advanced for drug-resistant epilepsy and inflammatory conditions, respectively. The Company leverages proprietary nano-delivery technologies designed to optimise bioavailability and tissue penetration, including across the blood–brain barrier and pulmonary interfaces. With vertically integrated EU-GMP manufacturing, a unified Neuro-Immune Modulatory platform, and ongoing clinical development programs, Argent BioPharma is advancing a focused pipeline targeting central nervous system and systemic inflammatory conditions with significant unmet medical need.

[1] Refer to ASX Announcement dated 17 November 2025